Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,590.88
(
-0.51%
)
US TECH 100
23,645.60
(
-0.63%
)
Dow Jones
45,945.41
(
-0.61%
)
Brent Oil
107.49
(
0.85%
)
Bitcoin
69,550.92
(
-2.37%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122797
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: io_io post# 28671

Monday, 05/15/2006 5:52:30 PM

Monday, May 15, 2006 5:52:30 PM

Post# of 257259
>I think the rap on ARDM is that the NovoNordisk phase II is going to take 2-3 years to enroll.<

Everyone knows that NVO/ARDM is a distant third in the inhaled-insulin arena, and this program isn’t costing ARDM any money. (NVO’s trials are phase-3, by the way.) The problems discussed on the CC have to do with the other facets of ARDM’s business.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now